Antibody Therapeutics Patients First!

공지사항


번호 제목 작성자 작성일 조회
26   Dr. Jin-San Yoo, CEO of PharmAbcine is attending and partnering at AusBiotech 2017 at Adelaid Convention Centre South Australia, on 25-27 October 2017.   관리자   2018-08-06   144  
25   PharmAbcine is sponsoring THE 10TH COGNO ANNUAL SCIENTIFIC MEETINGS (COOPERATIVE TRAILS GROUP FRO NEURO-ONCOLOGY) on Monday 23rd -Tuesday 24th October 2017.   관리자   2018-08-06   361  
24   Dr. Lawrence Cher is presenting Tanibirumab phase IIa interim data at THE 10TH COGNO ANNUAL SCIENTIFIC MEETINGS (COOPERATIVE TRAILS GROUP FRO NEURO-ONCOLOGY) on Monday 23rd -Tuesday 24th October 2017.   관리자   2018-08-06   168  
23   Dr. Jin-San Yoo, CEO of PharmAbcine is attending to THE 10TH COGNO ANNUAL SCIENTIFIC MEETINGS (COOPERATIVE TRAILS GROUP FRO NEURO-ONCOLOGY) on Monday 23rd -Tuesday 24th October 2017.   관리자   2018-08-06   156  
22   Dr. Jin-San Yoo, CEO of PharmAbcine is joining for the ``Critical Issues in Tumor Microenvironment: Angiogenesis, Metastasis and Immunology`` of Tumor Course of Harvard Medical School and for networking on September 5-8th, 2017.   관리자   2018-08-06   152  
21   Dr. Jin-San Yoo, CEO of PharmAbcine and Dr. Sung Woo Kim, Head of Business Development are requested to participate partnering meeting at INCHEON BIOPLUS 2017 - GLOBAL PARTNERING on September 13th, 2017.   관리자   2018-08-06   152  
20   Dr. Jin-San Yoo, CEO of PharmAbcine and Dr. Sung Woo Kim, Head of Business Development are requested to participate partnering meeting with Novartis BD&L on September 15th, 2017.   관리자   2018-08-06   154  
19   Dr. Jin-San Yoo, CEO of PharmAbcine will present as invited speaker at NOVARTIS GLOBAL PARTNERING CONFERENCE on September 14th, 2017.   관리자   2018-08-06   154  
18   Dr. Jin-San Yoo, CEO of PharmAbcine is invited to present as panelist at KoNECT-KDDF GLOBAL CLINICAL DEVELOPMENT FORUM on August 17th, 2017.   관리자   2018-08-06   155  
17   Dr. Lawrence Cher at Olivia Newton-Johns Cancer Wellness & Research Center/Austin Hospital is invited to present the interim data of Tanibirumab phase IIa recurrent GBM trial at 2017 SNO (Society for Neuro Oncology) meeting in San Francisco on November 16   관리자   2018-08-06   151